Investigating Gene Therapy Nexiguran Ziclumeran for ATTRv-PN: Phase 3 MAGNITUDE-2 Trial
Global site reactivation for the MAGNITUDE-2 trial of nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy is underway, with enrollment completion expected in the second half of 2026.
Welcome to NeurologyLive®'s Clinical Trial in Focus. Every month, an ongoing clinical trial in the landscape of neurology is featured, highlighting the design of the study, the targeted patient population, the enrollment criteria, the primary and secondary end points, and its potential implications for clinical care. This month’s spotlight is the phase 3 MAGNITUDE-2 trial (NCT06672237), assessing investigational gene therapy nexiguran ziclumeran (Intellia Therapeutics) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a rare genetic neuromuscular condition.